Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study.

Brosseron F, Kolbe CC, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S, Tacik P, Namasivayam AA, Mangone G, Schneider R, Latz E, Wüllner U, Svenningsson P, Sánchez-Valle R, Molinuevo JL, Corvol JC, Heneka MT; AETIONOMY study group.

Alzheimers Dement. 2019 Oct 17. pii: S1552-5260(19)35352-X. doi: 10.1016/j.jalz.2019.07.018. [Epub ahead of print]

PMID:
31630996
2.

Pain in persons with mild-moderate Parkinson's disease: a cross-sectional study of pain severity and associated factors.

Joseph C, Jonsson-Lecapre J, Wicksell R, Svenningsson P, Franzén E.

Int J Rehabil Res. 2019 Sep 19. doi: 10.1097/MRR.0000000000000373. [Epub ahead of print]

PMID:
31567485
3.

Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging.

Shariatgorji M, Nilsson A, Fridjonsdottir E, Vallianatou T, Källback P, Katan L, Sävmarker J, Mantas I, Zhang X, Bezard E, Svenningsson P, Odell LR, Andrén PE.

Nat Methods. 2019 Oct;16(10):1021-1028. doi: 10.1038/s41592-019-0551-3. Epub 2019 Sep 23.

PMID:
31548706
4.

Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson's Disease.

Green HF, Khosousi S, Svenningsson P.

J Parkinsons Dis. 2019;9(4):705-709. doi: 10.3233/JPD-191699.

PMID:
31524180
5.

Fluoxetine Suppresses Glutamate- and GABA-Mediated Neurotransmission by Altering SNARE Complex.

Lazarevic V, Mantas I, Flais I, Svenningsson P.

Int J Mol Sci. 2019 Aug 30;20(17). pii: E4247. doi: 10.3390/ijms20174247.

6.

Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study.

Puschmann A, Jiménez-Ferrer I, Lundblad-Andersson E, Mårtensson E, Hansson O, Odin P, Widner H, Brolin K, Mzezewa R, Kristensen J, Soller M, Rödström EY, Ross OA, Toft M, Breedveld GJ, Bonifati V, Brodin L, Zettergren A, Sydow O, Linder J, Wirdefeldt K, Svenningsson P, Nissbrandt H, Belin AC, Forsgren L, Swanberg M.

Parkinsonism Relat Disord. 2019 Sep;66:158-165. doi: 10.1016/j.parkreldis.2019.07.032. Epub 2019 Jul 31.

7.

Altered CSF levels of monoamines in hereditary spastic paraparesis 10: A case series.

Andréasson M, Lagerstedt-Robinson K, Samuelsson K, Solders G, Blennow K, Paucar M, Svenningsson P.

Neurol Genet. 2019 Jun 12;5(4):e344. doi: 10.1212/NXG.0000000000000344. eCollection 2019 Aug.

8.

The cerebellar phenotype of Charcot-Marie-Tooth neuropathy type 4C.

Skott H, Muntean-Firanescu C, Samuelsson K, Verrecchia L, Svenningsson P, Malmgren H, Cananau C, Espay AJ, Press R, Solders G, Paucar M.

Cerebellum Ataxias. 2019 Jul 15;6:9. doi: 10.1186/s40673-019-0103-8. eCollection 2019.

9.

GRP78 Level Is Altered in the Brain, but Not in Plasma or Cerebrospinal Fluid in Parkinson's Disease Patients.

Baek JH, Mamula D, Tingstam B, Pereira M, He Y, Svenningsson P.

Front Neurosci. 2019 Jul 5;13:697. doi: 10.3389/fnins.2019.00697. eCollection 2019.

10.

α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients.

Paslawski W, Zareba-Paslawska J, Zhang X, Hölzl K, Wadensten H, Shariatgorji M, Janelidze S, Hansson O, Forsgren L, Andrén PE, Svenningsson P.

Proc Natl Acad Sci U S A. 2019 Jul 23;116(30):15226-15235. doi: 10.1073/pnas.1821409116. Epub 2019 Jul 3.

11.

Vertical saccades and antisaccades: complementary markers for motor and cognitive impairment in Parkinson's disease.

Waldthaler J, Tsitsi P, Svenningsson P.

NPJ Parkinsons Dis. 2019 Jun 24;5:11. doi: 10.1038/s41531-019-0083-7. eCollection 2019.

12.

Editorial: Update on movement disorders.

Svenningsson P, Frucht SJ.

Curr Opin Neurol. 2019 Aug;32(4):564-565. doi: 10.1097/WCO.0000000000000709. No abstract available.

PMID:
31246704
13.

Update on movement disorders.

Svenningsson P, Frucht SJ.

Curr Opin Neurol. 2019 Jun 18. doi: 10.1097/WCO.0000000000000709. [Epub ahead of print] No abstract available.

PMID:
31219826
14.

Involuntary movements, vocalizations and cognitive decline.

Sveinsson O, Udd B, Svenningsson P, Gassner C, Engström C, Laffita-Mesa J, Solders G, Hertegård S, Savitcheva I, Jung HH, Tolnay M, Frey BM, Paucar M.

Parkinsonism Relat Disord. 2019 May 29. pii: S1353-8020(19)30250-0. doi: 10.1016/j.parkreldis.2019.05.029. [Epub ahead of print] No abstract available.

PMID:
31153763
15.

MCEE Mutations in an Adult Patient with Parkinson's Disease, Dementia, Stroke and Elevated Levels of Methylmalonic Acid.

Andréasson M, Zetterström RH, von Döbeln U, Wedell A, Svenningsson P.

Int J Mol Sci. 2019 May 29;20(11). pii: E2631. doi: 10.3390/ijms20112631.

16.

Corticobasal degeneration: advances in clinicopathology and biomarkers.

Svenningsson P.

Curr Opin Neurol. 2019 Aug;32(4):597-603. doi: 10.1097/WCO.0000000000000707.

PMID:
31145128
17.

GBA RNAi but not catalytic inhibition of glucocerebrosidase with Conduritol-β-epoxide increases levels of total α-synuclein in SH-SY5Y cells.

Zurbruegg M, Chan MY, Svenningsson P.

Neurosci Lett. 2019 Jul 27;706:217-222. doi: 10.1016/j.neulet.2019.05.027. Epub 2019 May 15.

PMID:
31102708
18.

Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholinesterase inhibition.

Vallianatou T, Shariatgorji M, Nilsson A, Fridjonsdottir E, Källback P, Schintu N, Svenningsson P, Andrén PE.

Neuropsychopharmacology. 2019 Nov;44(12):2091-2098. doi: 10.1038/s41386-019-0397-5. Epub 2019 Apr 22.

PMID:
31009936
19.

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism.

Sjöström H, Surova Y, Nilsson M, Granberg T, Westman E, van Westen D, Svenningsson P, Hansson O.

Sci Rep. 2019 Apr 15;9(1):6079. doi: 10.1038/s41598-019-42565-4.

20.

Binding of α-synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes.

Reyes JF, Sackmann C, Hoffmann A, Svenningsson P, Winkler J, Ingelsson M, Hallbeck M.

Acta Neuropathol. 2019 Jul;138(1):23-47. doi: 10.1007/s00401-019-02007-x. Epub 2019 Apr 11.

21.

First Clinicogenetic Description of Parkinson's Disease Related to GBA Mutation S107L.

Hertz E, Thörnqvist M, Holmberg B, Machaczka M, Sidransky E, Svenningsson P.

Mov Disord Clin Pract. 2019 Mar 7;6(3):254-258. doi: 10.1002/mdc3.12743. eCollection 2019 Mar.

PMID:
30949558
22.

SQSTM1/p62-Directed Metabolic Reprogramming Is Essential for Normal Neurodifferentiation.

Calvo-Garrido J, Maffezzini C, Schober FA, Clemente P, Uhlin E, Kele M, Stranneheim H, Lesko N, Bruhn H, Svenningsson P, Falk A, Wedell A, Freyer C, Wredenberg A.

Stem Cell Reports. 2019 Apr 9;12(4):696-711. doi: 10.1016/j.stemcr.2019.01.023. Epub 2019 Feb 28.

23.

Attenuated beta rebound to proprioceptive afferent feedback in Parkinson's disease.

Vinding MC, Tsitsi P, Piitulainen H, Waldthaler J, Jousmäki V, Ingvar M, Svenningsson P, Lundqvist D.

Sci Rep. 2019 Feb 22;9(1):2604. doi: 10.1038/s41598-019-39204-3.

24.

Decreased Cerebrospinal Fluid Aβ42 in Patients with Idiopathic Parkinson's Disease and White Matter Lesions.

Markaki I, Klironomos S, Svenningsson P.

J Parkinsons Dis. 2019;9(2):361-367. doi: 10.3233/JPD-181486.

PMID:
30714972
25.

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.

Green H, Tsitsi P, Markaki I, Aarsland D, Svenningsson P.

CNS Drugs. 2019 Feb;33(2):143-160. doi: 10.1007/s40263-018-0601-x. Review.

26.

On the fluxes of side-chain oxidized oxysterols across blood-brain and blood-CSF barriers and origin of these steroids in CSF (Review).

Björkhem I, Leoni V, Svenningsson P.

J Steroid Biochem Mol Biol. 2019 Apr;188:86-89. doi: 10.1016/j.jsbmb.2018.12.009. Epub 2018 Dec 23. Review.

PMID:
30586624
27.

Variant ataxia-telangiectasia with prominent camptocormia.

Paucar M, Schechtmann G, Taylor AM, Svenningsson P.

Parkinsonism Relat Disord. 2019 May;62:253-255. doi: 10.1016/j.parkreldis.2018.12.017. Epub 2018 Dec 17. No abstract available.

PMID:
30579816
28.

Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial.

Svenningsson P, Johansson A, Nyholm D, Tsitsi P, Hansson F, Sonesson C, Tedroff J.

NPJ Parkinsons Dis. 2018 Dec 6;4:35. doi: 10.1038/s41531-018-0071-3. eCollection 2018.

29.

GPR37 and GPR37L1 differently interact with dopamine 2 receptors in live cells.

Hertz E, Terenius L, Vukojević V, Svenningsson P.

Neuropharmacology. 2019 Jul 1;152:51-57. doi: 10.1016/j.neuropharm.2018.11.009. Epub 2018 Nov 10.

30.

WITHDRAWN: Novel Xp21.1 deletion associated with unusual features in a large McLeod syndrome kindred.

Sveinsson O, Udd B, Svenningsson P, Gassner C, Engström C, Laffita-Mesa JM, Solders G, Hertegård S, Savitcheva I, Jung HH, Tolnay M, Frey BM, Paucar M.

Parkinsonism Relat Disord. 2018 Oct 8. pii: S1353-8020(18)30399-7. doi: 10.1016/j.parkreldis.2018.09.014. [Epub ahead of print] No abstract available.

PMID:
30305234
31.

Eye movements during reading in Parkinson's disease: A pilot study.

Waldthaler J, Tsitsi P, Seimyr GÖ, Benfatto MN, Svenningsson P.

Mov Disord. 2018 Oct;33(10):1661-1662. doi: 10.1002/mds.105. Epub 2018 Oct 8. No abstract available.

PMID:
30298615
32.

Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.

Fazio P, Paucar M, Svenningsson P, Varrone A.

Curr Neurol Neurosci Rep. 2018 Oct 5;18(12):85. doi: 10.1007/s11910-018-0890-y. Review.

33.

PET imaging of [11C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding.

Varnäs K, Cselényi Z, Jucaite A, Halldin C, Svenningsson P, Farde L, Varrone A.

Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):367-375. doi: 10.1007/s00259-018-4161-6. Epub 2018 Oct 1.

34.

24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome.

Björkhem I, Patra K, Boxer AL, Svenningsson P.

Front Neurol. 2018 Sep 7;9:756. doi: 10.3389/fneur.2018.00756. eCollection 2018.

35.

Riluzole attenuates the efficacy of glutamatergic transmission by interfering with the size of the readily releasable neurotransmitter pool.

Lazarevic V, Yang Y, Ivanova D, Fejtova A, Svenningsson P.

Neuropharmacology. 2018 Dec;143:38-48. doi: 10.1016/j.neuropharm.2018.09.021. Epub 2018 Sep 14.

PMID:
30222983
36.

Chorea, psychosis, acanthocytosis, and prolonged survival associated with ELAC2 mutations.

Paucar M, Pajak A, Freyer C, Bergendal Å, Döry M, Laffita-Mesa JM, Stranneheim H, Lagerstedt-Robinson K, Savitcheva I, Walker RH, Wedell A, Wredenberg A, Svenningsson P.

Neurology. 2018 Oct 9;91(15):710-712. doi: 10.1212/WNL.0000000000006320. Epub 2018 Sep 14. No abstract available.

37.

Pathological Study of a FMR1 Premutation Carrier With Progressive Supranuclear Palsy.

Paucar M, Nennesmo I, Svenningsson P.

Front Genet. 2018 Aug 15;9:317. doi: 10.3389/fgene.2018.00317. eCollection 2018.

38.

Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition.

Siebzehnrübl FA, Raber KA, Urbach YK, Schulze-Krebs A, Canneva F, Moceri S, Habermeyer J, Achoui D, Gupta B, Steindler DA, Stephan M, Nguyen HP, Bonin M, Riess O, Bauer A, Aigner L, Couillard-Despres S, Paucar MA, Svenningsson P, Osmand A, Andreew A, Zabel C, Weiss A, Kuhn R, Moussaoui S, Blockx I, Van der Linden A, Cheong RY, Roybon L, Petersén Å, von Hörsten S.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8765-E8774. doi: 10.1073/pnas.1807962115. Epub 2018 Aug 27.

39.

GLRA1 mutation and long-term follow-up of the first hyperekplexia family.

Paucar M, Waldthaler J, Svenningsson P.

Neurol Genet. 2018 Aug 7;4(4):e259. doi: 10.1212/NXG.0000000000000259. eCollection 2018 Aug. No abstract available.

40.

Dynamic lateral organization of opioid receptors (kappa, muwt and muN40D ) in the plasma membrane at the nanoscale level.

Rogacki MK, Golfetto O, Tobin SJ, Li T, Biswas S, Jorand R, Zhang H, Radoi V, Ming Y, Svenningsson P, Ganjali D, Wakefield DL, Sideris A, Small AR, Terenius L, Jovanović-Talisman T, Vukojević V.

Traffic. 2018 May 28. doi: 10.1111/tra.12582. [Epub ahead of print]

41.

Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.

Jaiteh M, Zeifman A, Saarinen M, Svenningsson P, Bréa J, Loza MI, Carlsson J.

J Med Chem. 2018 Jun 28;61(12):5269-5278. doi: 10.1021/acs.jmedchem.8b00204. Epub 2018 Jun 15.

42.

Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine.

Zhang X, Mantas I, Alvarsson A, Yoshitake T, Shariatgorji M, Pereira M, Nilsson A, Kehr J, Andrén PE, Millan MJ, Chergui K, Svenningsson P.

Front Pharmacol. 2018 Mar 1;9:166. doi: 10.3389/fphar.2018.00166. eCollection 2018.

43.

Novel Features and Abnormal Pattern of Cerebral Glucose Metabolism in Spinocerebellar Ataxia 19.

Paucar M, Bergendal Å, Gustavsson P, Nordenskjöld M, Laffita-Mesa J, Savitcheva I, Svenningsson P.

Cerebellum. 2018 Aug;17(4):465-476. doi: 10.1007/s12311-018-0927-4.

44.

Nigrostriatal dopamine transporter availability in early Parkinson's disease.

Fazio P, Svenningsson P, Cselényi Z, Halldin C, Farde L, Varrone A.

Mov Disord. 2018 Apr;33(4):592-599. doi: 10.1002/mds.27316. Epub 2018 Feb 13.

PMID:
29436751
45.

A mass spectrometry imaging approach for investigating how drug-drug interactions influence drug blood-brain barrier permeability.

Vallianatou T, Strittmatter N, Nilsson A, Shariatgorji M, Hamm G, Pereira M, Källback P, Svenningsson P, Karlgren M, Goodwin RJA, Andrén PE.

Neuroimage. 2018 May 15;172:808-816. doi: 10.1016/j.neuroimage.2018.01.013. Epub 2018 Jan 10.

PMID:
29329980
46.

Paroxysmal Kinesigenic Dyskinesia.

Paucar M, Malmgren H, Svenningsson P.

Tremor Other Hyperkinet Mov (N Y). 2017 Dec 12;7:529. doi: 10.7916/D8R79N2F. eCollection 2017.

47.

Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.

Yao N, Skiteva O, Zhang X, Svenningsson P, Chergui K.

Mol Psychiatry. 2018 Oct;23(10):2066-2077. doi: 10.1038/mp.2017.239. Epub 2017 Nov 21.

PMID:
29158578
48.

Patient-driven N-of-1 in Parkinson's Disease. Lessons Learned from a Placebo-controlled Study of the Effect of Nicotine on Dyskinesia.

Riggare S, Unruh KT, Sturr J, Domingos J, Stamford JA, Svenningsson P, Hägglund M.

Methods Inf Med. 2017 Oct 24;56(99):e123-e128. doi: 10.3414/ME16-02-0040. Epub 2017 Oct 24.

49.

Quantitative susceptibility mapping differentiates between parkinsonian disorders.

Sjöström H, Granberg T, Westman E, Svenningsson P.

Parkinsonism Relat Disord. 2017 Nov;44:51-57. doi: 10.1016/j.parkreldis.2017.08.029. Epub 2017 Sep 1.

PMID:
28886909
50.

Correlations Between Methionine Cycle Metabolism, COMT Genotype, and Polyneuropathy in L-Dopa Treated Parkinson's Disease: A Preliminary Cross-Sectional Study.

Andréasson M, Brodin L, Laffita-Mesa JM, Svenningsson P.

J Parkinsons Dis. 2017;7(4):619-628. doi: 10.3233/JPD-171127.

PMID:
28759974

Supplemental Content

Loading ...
Support Center